Alkem Laboratories posted a consolidated net profit of ₹675 crore for the second quarter ended September 30, 2026, marking a 12 percent decline. Total revenue from operations grew by 13.8 percent to ₹4,552 crore, though biotech sales faced a 35 percent drop due to the lumpy nature of the CDMO business.

Alkem Laboratories has reported a consolidated net profit of ₹675 crore for the second quarter ended September 30, 2026, marking a drop of nearly 12 percent compared to the same period in the previous year.

Despite the decline in net profit, the company posted a total revenue from operations of ₹4,552 crore, representing a 13.8 percent increase year-on-year. According to Managing Director Sandeep Singh, the performance was driven by continued momentum in the domestic market, supported by execution across acute and chronic portfolios.

India sales contributed significantly to the top line, standing at ₹3,027 crore and registering a 9.5 percent growth over the previous year, accounting for over 60 percent of the company's total revenue. Meanwhile, international sales reached ₹1,454 crore, growing 22.3 percent despite ongoing pricing pressures in the US market, which were offset by volume growth.

The company's biotech segment experienced a setback during the quarter, with sales declining by 35 percent to ₹70 crore. Singh attributed this degrowth to the 'lumpy' nature of the contract development and manufacturing organization (CDMO) business. Enzene, Alkem's biologicals arm, and the newly expanded MedTech presence—bolstered by the addition of Occlutech—remain key strategic priorities. Medtech sales for the quarter stood at ₹133 crore, including Occlutech. Additionally, Dr. Amrut Naik was recently appointed as the Chief Executive Officer for the biologicals business.

On the regulatory front, Singh informed analysts that remediation efforts are currently underway at the Daman facility to address an Official Action Indicated (OAI) observation from the US Food and Drug Administration (USFDA). Separately, the USFDA inspection at the Mandva active pharmaceutical ingredients facility concluded without any Form 483 observations.

Alkem Laboratories closed the quarter ending September 30, 2026, with a net cash position of ₹4,905 crore.

"Alkem Laboratories' Q2 performance highlights a common reality in the pharmaceutical sector, where strong domestic demand and international volume growth can coexist with margin pressures and segment-specific volatility. The dip in biotech sales due to the lumpy nature of the CDMO model underscores the importance of revenue diversification. For growing enterprises, balancing core market execution with long-term strategic investments in biologicals and medtech—while actively managing regulatory compliance—remains critical to sustaining overall financial health." — Dr. Shishir Gupta, Founder & CEO, StartupLanes

Recent StartupLanes Articles

Browse through our 30 latest publications on venture capital, startups, and angel investing.

Alkem Laboratories Reports Q2 FY27 Net Profit Down 12% at ₹675 Crore Nov 15, 2026
Indian Equities Set for Muted Opening as Crude Prices and Inflation Offset Foreign Inflows Nov 15, 2026
Market Updates: SoftBank Affiliate Likely to Sell Meesho Stake, Clean Max Commits ₹50,000 Crore in Andhra Pradesh, and Ola Posts Q2 Loss Nov 15, 2026
Market Watch: SBI Life Insurance Shows Upward Trend as Manappuram Finance Reports Strong Quarterly Financials Nov 15, 2026
Nvidia CEO Jensen Huang Resigns Amid Conduct Scandal and China Intelligence Inquiries Nov 15, 2026
Scrutiny Mounts on Nvidia Leadership Following Further Reports Regarding Former CEO Jensen Huang's Personal Conduct Nov 15, 2026
Former Nvidia CEO Jensen Huang Agrees to Testify in US Congressional Probe Over Alleged China Links Nov 15, 2026
US Immigration and Customs Enforcement Reports Record 4,83,200 Deportations Nov 15, 2026
Anthropic Seeks $64.4 Billion in Proposed IPO as Share Demand Reaches Sixfold Nov 15, 2026
Study Finds Crows Make Visual Decisions Twice as Fast as Humans Nov 15, 2026
Nvidia Co-founder Jensen Huang Steps Down Amid Controversy; CFO Colette Kress Appointed Interim CEO Nov 15, 2026
Microsoft Outage Disrupts Outlook, Teams and Microsoft 365 Services Nov 15, 2026
ISRO Successfully Tests Upgraded PSLV Third Stage Following Previous Mission Anomalies Nov 15, 2026
India aims to roll out fully indigenous civil aircraft in two years, says Aviation Minister Nov 15, 2026
Nvidia CEO Jensen Huang Resigns Amid Conduct Inquiries and US-China Scrutiny Nov 15, 2026
India's Outbound Direct Investment Growth Moderates to 9.4% in H1 FY27 Nov 15, 2026
India’s PLI Schemes Attract ₹2.40 Lakh Crore in Investments and Drive ₹22.66 Lakh Crore in Production Nov 15, 2026
Union Cabinet Approves ₹62,370-Crore Rabi Fertilizer Subsidy as Global Input Prices Rise Nov 15, 2026
Union Bank of India Increases Stake in Star Union Dai-ichi Life with ₹336.51 Crore Investment Nov 15, 2026
Star Health Launches Young Star NEO to Increase Insurance Penetration Among Young Demographic Nov 15, 2026
Power Ministry Issues Advisory to Align Thermal Power Plant Commissioning with Transmission and Fuel Supply Nov 15, 2026
Reliance, Amara Raja, and Exide Among 22 Bidders for 10 GWh Battery Storage PLI Capacity Nov 15, 2026
Defence Minister Rajnath Singh Urges IAF to Develop Doctrines for Cyber and Space Warfare Nov 15, 2026
Nvidia Loses $300 Billion in Market Value Amid Leadership Scrutiny and AI Sector Downturn Nov 15, 2026
Early Contenders Emerge for 2028 US Presidential Race as Per Reuters/Ipsos Poll Nov 15, 2026
Akasa Air Q1 FY27 Net Loss Widens to ₹550 Crore Amid Capital Infusion and Fleet Expansion Nov 15, 2026
Prism Johnson Reports Q2FY27 EBITDA at ₹190 Crore, Net Debt Reduces to ₹467 Crore Nov 15, 2026
Brazil's WEG to Establish Manufacturing Plant in Tamil Nadu with ₹2,000 Crore Investment Nov 15, 2026
Mahindra & Mahindra Sees Strong Demand Across SUV and Tractor Segments Amid Favorable Market Conditions Nov 15, 2026
AMD to Make Equity Investment in PsiQuantum to Advance Quantum Computing Infrastructure Nov 15, 2026